MedTrace Logo

An Observational Study of NeoRecormon (Epoetin Beta) in Cancer Patients With Anemia (FAST)

NCT01168349 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1060

Last updated 2015-10-02

Study results available
· View outcomes & findings →

Summary

This observational study will evaluate the clinical benefit of NeoRecormon (epoetin beta) in daily routine practice in cancer patients with anemia. Data will be collected from patients who are receiving chemotherapy for a solid tumor or hematological malignancy. Patients will be followed for 28 weeks.

Conditions

  • Anemia, Neoplasms

Interventions

DRUG

epoetin beta [NeoRecormon]

As prescribed by physician

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01168349 on ClinicalTrials.gov